Managing Induction: Toxicity, Patient Counseling, and Five-Year Survival Data

In this segment, our panel prepares you for what to expect when you start a patient on tebentafusp, covering the toxicity profile in practical detail and explaining why the first few doses look very different from what comes later. You will hear how to counsel patients before they arrive for their first infusion, what a typical induction experience looks like including rash, fever, and cytokine release, and how to manage these reactions proactively with antihistamines, antibiotics, and fluids. The panel also presents the five-year overall survival data from the pivotal Phase 3 trial, putting the sustained survival advantage in context and discussing what it means that a meaningful proportion of long-term survivors received tebentafusp as their only therapy with no subsequent treatment required.